Skip to main content

Web Content Display Web Content Display

Web Content Display Web Content Display

Web Content Display Web Content Display

Monitoring of the genetic variability of the SARS-CoV-2 virus in Poland

 

 

 

 

 

 

Project name: Monitoring of the genetic variability of the SARS-CoV-2 virus in Poland.

Research co-financing from the state budget from the Medical Research Agency, project number: 2020 / ABM / COVID19 / UJ.

Co-financing value: PLN 7,634,880.00

The total cost of the project: PLN 7,634,880.00

 

The Malopolska Center of Biotechnology conducts research in cooperation with the Medical Research Agency. Its main goal is to monitor the variability and evolution of the SARS-CoV-2 virus in Poland. The project is a response to the need to carry out a nationwide geno-epidemiological study of SARS-CoV-2 genetic variants in the country and the need to monitor the threats that new genetic variants may cause.

As part of the research, in close cooperation with Main Sanitary Inspectorate and diagnostic laboratories, the sequencing of virus isolates representative for the whole country will be successively carried out. The obtained data will then be subjected to bioinformatics and phylogenetic analysis. The SARS-CoV-2 sequences will be collected in public databases (GISAID and NCBI), and the results of the analysis will be gathered in the local database presenting the current distribution of strains in Poland. The results of the analyzes for Poland can already be found at http://sarswpolsce.pl/. The work schedule assumes the completion of the above-mentioned stages by January 31, 2022.

 

What can the results of this project be used for?

• Monitoring the presence of potentially dangerous variants of the VOC (a variant of concern) and correlation with the phases of the epidemic.

• Identification of changes in the viral genome that have the potential to alter transmission capacity, disease progression, or sensitivity to our immune system response.

• Rapid identification of changes that may cause loss of sensitivity and uselessness of the currently used diagnostic tests.

• Identification potential drug-resistant variants (if antiviral drugs emerge).